Ramaco Resources posted a net loss of $18.2 million in Q3 2026 but maintained strong liquidity of $375 million, up 38% year-over-year. The company secured 1.7 million tons of domestic coal sales for 2027 at $139 per ton, signaling growth despite current market challenges. It also advanced its rare earth and critical minerals project in Wyoming, with pilot plant construction underway and pre-feasibility study expected in 2027. Ramaco expects improved margins in Q4 2026 and 2027, supported by strong sales commitments and cost controls amid rising diesel prices.
Ramaco Resources' Q3 2026 results provide context for readers following the Basic Materials sector. For readers following Basic Materials, here is Pluang's market snapshot as of Nov 04, 2026 04:11 WIB: out of 83 priced US stocks, 13 rose and 69 fell. Notable movers include DuPont de Nemours Inc (DD) at USD 152.88 with a 1-day change of +8.12%, Harmony Gold Mining Co. (HMY) at USD 14.50 down 7.82%, and Americas Gold and Silver Corporation (USAS) at USD 2.69 down 6.60%.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
